World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
92
Citations
34924
World Ranking
11208
National Ranking
409

Overview

Pellegrino Musto is affiliated with the University of Bari Aldo Moro in Italy. The primary field of their research is Medicine, with a focus on subfields such as Hematology, Molecular Biology, Oncology, Genetics, and Infectious Diseases.

Their research covers several main topics including:

  • Multiple Myeloma Research and Treatments
  • Acute Myeloid Leukemia Research
  • Protein Degradation and Inhibitors
  • Chronic Lymphocytic Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • Chronic Myeloid Leukemia Treatments
  • SARS-CoV-2 and COVID-19 Research

Pellegrino Musto has contributed to numerous publications in a variety of venues. Their frequent publication venues include:

  • Blood
  • HemaSphere
  • Hematological Oncology
  • Haematologica
  • Cancers

Several recurring coauthors have collaborated extensively with them, including:

  • Giorgina Specchia
  • Francesco Albano
  • Mario Boccadoro
  • Nicola Sgherza
  • Francesca Gay

Notable recent papers authored include:

  • Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study (2020, The Lancet Haematology)
  • Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage (2021, Blood Cancer Journal)
  • Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network (2023, The Lancet Oncology)
  • High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma (2022, Journal of Clinical Oncology)
  • Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial (2022, The Lancet Oncology)

Best Publications

  • Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

    Antonio Palumbo;Hervé Avet-Loiseau;Stefania Oliva;Henk M. Lokhorst

  • BRAF mutations in hairy-cell leukemia

    Enrico Tiacci;Vladimir Trifonov;Gianluca Schiavoni;Antony Holmes

  • Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

    Antonio Palumbo;Sara Bringhen;Tommaso Caravita;Emanuela Merla

  • Cardiovascular Events and Intensity of Treatment in Polycythemia Vera

    Roberto Marchioli;Guido Finazzi;Giorgina Specchia;Rossella Cacciola

  • Autologous transplantation and maintenance therapy in multiple myeloma

    Antonio Palumbo;Federica Cavallo;Francesco Di Raimondo

  • Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

    Antonio Palumbo;Sara Bringhen;Maria Victoria Mateos;Alessandra Larocca

  • Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.

    Philip L. McCarthy;Sarah A. Holstein;Maria Teresa Petrucci;Paul G. Richardson

  • Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial

    Antonio Palumbo;Sara Bringhen;Davide Rossi;Maide Cavalli

  • Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study.

    Francesco Passamonti;Chiara Cattaneo;Luca Arcaini;Riccardo Bruna

  • Efficacy and safety of once-weekly bortezomib in multiple myeloma patients

    Sara Bringhen;Alessandra Larocca;Davide Rossi;Maide Cavalli

  • Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.

    Antonio Palumbo;Sara Bringhen;Anna M. Liberati;Tommaso Caravita

  • Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

    Michele Cavo;Lucia Pantani;Maria Teresa Petrucci;Francesca Patriarca

  • European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications

    Evangelos Terpos;Martina Kleber;Monika Engelhardt;Sonja Zweegman

  • Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA—Italian Multiple Myeloma Network

    Antonio Palumbo;Patrizia Falco;Paolo Corradini;Antonietta Falcone

  • Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial

    Antonio Palumbo;Sara Bringhen;Maria Teresa Petrucci;Pellegrino Musto

  • Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study.

    Livio Pagano;Caterina Giovanna Valentini;Alessandro Pulsoni;Simona Fisogni

  • Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study

    Alfonso Mele;Alessandro Pulsoni;Elvira Bianco;Pellegrino Musto

  • ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial

    Massimo Federico;Stefano Luminari;Emilio Iannitto;Giuseppe Polimeno

  • Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials

    Peter M. Fayers;Peter M. Fayers;Antonio Palumbo;Cyrille Hulin;Anders Waage

  • Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients

    Alessandra Larocca;Pierre Wijermans;Federica Cavallo

Frequent Co-Authors

Antonio Palumbo
Antonio Palumbo University of Turin
Mario Boccadoro
Mario Boccadoro University of Turin
Maria Teresa Petrucci
Maria Teresa Petrucci Sapienza University of Rome
Francesco Di Raimondo
Francesco Di Raimondo University of Catania
Michele Cavo
Michele Cavo University of Bologna
Gianluca Gaidano
Gianluca Gaidano University of Eastern Piedmont Amadeo Avogadro
Antonino Neri
Antonino Neri University of Milan
Paolo Corradini
Paolo Corradini University of Milan
Giorgina Specchia
Giorgina Specchia University of Bari Aldo Moro
Federica Cavallo
Federica Cavallo University of Turin

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a career in medicine opens up various educational routes beyond the traditional MD. Many students explore flexible online nursing degrees as both an entry point to healthcare and a stepping-stone for future advancement. For those seeking convenience and affordability, a nursing degree online offers foundational courses and practical experience, often with lower tuition costs.

Registered nurses looking to advance their careers often pursue a Bachelor of Science in Nursing. The cheapest rn to bsn online programs allow RNs to increase their qualifications flexibly and affordably, without putting their careers on hold.

For those aiming for senior clinical or academic roles, a Doctor of Nursing Practice (DNP) can be a good choice. The cheapest dnp online program list helps find cost-effective options for building leadership and research skills in nursing.

If you hold a non-nursing bachelor’s degree but want to become a nurse practitioner, direct entry nurse practitioner programs for non-nurses online provide an accelerated path into advanced practice nursing, making the transition to a medical career more accessible than ever.

Best Scientists Citing Pellegrino Musto

Trending Scientists